ChemicalBook Product Catalog API Blood System Drugs Anticoagulant and Antiplatelet Drugs Inclacumab

Inclacumab

Product NameInclacumab
CAS1256258-86-2
MF
MW0
EINECS
MOL FileMol File

Chemical Properties

form	Liquid
color	Colorless to light yellow

Usage And Synthesis

Uses

Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 μg/mL and strongly inhibits cell adhesion[1][2][3].

in vivo

Inclacumab (4 mg/kg; s.c. once) reduces TRAP- and ADP-induced PLA levels in cynomolgus monkeys^[3]. Inclacumab (2-50 mg/kg; i.v.; once a week for 13 weeks) inhibits TRAP induced PLA levels in cynomolgus monkeys^[3].

Animal Model:	Cynomolgus monkeys^[3]
Dosage:	4 mg/kg
Administration:	Subcutaneous injection; 4 mg/kg; once
Result:	Significantly reduced TRAP-induced PLA levels from 25% to 6% and supressed PLA formation ≥80% for at least 28 days post treatment. Remained plasma concentrations >20 μg/mL during post treatment for 28 days. Significantly inhibited the formation of ADP (10 μM)-induced PLAs.

Animal Model:	Cynomolgus monkeys^[3]
Dosage:	2, 10, and 50 mg/kg
Administration:	Intravenous injection; once daily; for 13 weeks
Result:	Inhibited TRAP-induced PLA and remained concentrations at all three dose levels are higher than 20 μg/mL. Persisted the full inhibition of PLA formation between dosing period.

References

[1] Tarasev M, et al. S107: P-SELECTIN INHIBITOR INCLACUMAB REDUCES CELL ADHESION IN AN IN-VITRO ASSAYS SHOWING POTENTIAL FOR PREVENTION OF VASO-OCCLUSION EVENTS IN SICKLE CELL DISEASE. Hemasphere. 2022 Jan 31;6(Suppl ):3-4.
[2] Xin Geng, et al. Inclacumab, a Fully Human Anti-P-Selectin Antibody, Directly Binds to PSGL-1 Binding Region and Demonstrates Robust and Durable Inhibition of Cell Adhesion. Blood (2020) 136 (Supplement 1): 10–11.
[3] Kling D, et al. Pharmacological control of platelet-leukocyte interactions by the human anti-P-selectin antibody inclacumab--preclinical and clinical studies. Thromb Res. 2013 May;131(5):401-10. DOI:10.1016/j.thromres.2013.02.020

Inclacumab Supplier

Related Product Information

Send Inquriy